Silver Book Fact
Galantamine, a cholinesterase inhibitor, delays Alzheimer’s patients’ need for full-time care, with overall cost savings estimated between $323 and $4,256 per patient.
Caro J, Getsios D, Migliaccio-Walle K, Ishak J, et al. Rational Choice of Cholinesterase Inhibitor for the Treatment of Alzheimer s Disease in Canada: A comparative economic analysis. BMC Geriatrics. 2003; 3(6). http://www.biomedcentral.com/1471-2318/3/6